Incidence
Prevalence of Gaucher disease Type 1 (non-neuronopathic): 1 in 50,000-100,000 in the general population, worldwide;7 and approximately 1 in 350-450 people of Ashkenazi Jewish heritage8. The incidence of ASMD is estimated at 0.5 per 100,000 births.2
Program eligibility
The Roadmap2Rare Diagnostic Program* consists of parallel testing of both glucocerebrosidase and acid sphingomyelinase (ASM) enzyme assays with reflex to DNA sequencing of GBA or SMPD1 as appropriate, for individual patients with:
- Symptoms suggestive of Gaucher disease or ASMD
- Presumptive positive newborn screens for either disorder
*This testing program is not appropriate for carrier testing.
About the test
- Glucocerebrosidase enzyme assay (includes ASM enzyme assay in parallel) and if deficient will reflex to,
- GBA sequencing and Lyso-GL1 or SMPD1 sequencing as appropriate
- If either enzyme assay or GBA/SMPD1 sequencing has already been performed, these tests can be ordered individually, if needed.
References
1. Baris HN, Cohen IJ, Mistry PK. Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history. Pediatr Endocrinol Rev. 2014;12:72-81.
2. McGovern MM, Avetisyan R, Sanson BJ, Lidove O. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet J Rare Dis. 2017;12(1):41.
3. Wasserstein MP, Schuchman EH. Acid sphingomyelinase deficiency. NCBI GeneReviews (2015). Available at: ncbi.nlm.nih.gov/books/NBK1370/. Accessed July 19, 2018.
4. Kaplan P, Andersson HC, Kacena KA, et al. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med. 2006;160:603-608.
5. McGovern MM, Dionisi-vici C, Giugliani R, et al. Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency. Genet Med. 2017;19(9):967-974.
6. Simpson WL, Hermann G, Balwani M. Imaging of Gaucher disease. World J Radiol. 2014;6:657-668.
7. Mistry PK, Cappellini MD, Lukina E, et al. Consensus conference: a reappraisal of Gaucher disease – diagnosis and disease management algorithms. Am J Hematol. 2011;86(1):110-5.
8. Bronstein S, Karpati M, Peleg L. An update of Gaucher mutations distribution in the Ashkenazi Jewish population: prevalence and country of origin of the mutation R496H. Isr Med Assoc J. 2014;16:683-685.
This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location. The content on this page is provided for informational purposes only, not as medical advice. It is not intended to substitute the consultation, diagnosis, and/or treatment provided by a qualified licensed physician or other medical professionals.